Igm Biosciences, Inc.

Sutro Biopharma, Inc.

Cytokinetics, Inc.

Igm Biosciences A/s

Ramesh Baliga

Bruce Alan Keyt

Leonard G Presta

Christopher D Thanos

Gang Yin

Kalyani Penta

Avinash Gill

Leslie McEvoy

Sunil Bajad

Sonia Pollitt

Chris Murray

Alex Steiner

Fen Zhang

Dean Ng

Beatrice Tien-Yi Wang

Max Allen Schwarzer

Jeffrey T Finer

Stephen Fitzhugh Carroll

Erik Zimmerman

Daniel W Pierce

Donglin Guo

Omar Duramad

Beatrice Wang

Leonard George Presta

Fan Zhang

Provided herein are modified Fc proteins comprising non-natural amino acid residues at site-specific positions, conjugates of the modified Fc proteins for therapy or diagnosis, compositions comprising the modified Fc proteins and conjugates thereof, methods of their production and methods of their use. The modified Fc proteins and conjugates are useful for methods of treatment and prevention, methods of detection and methods of diagnosis.

Modified Fc proteins comprising site-specific non-natural amino acid residues, conjugates of the same, methods of their preparation and methods of their use

Provided herein are antibodies comprising non-natural amino acid residues at site-specific positions, compositions comprising the antibodies, methods of their production and methods of their use. The antibodies are useful for methods of treatment and prevention, methods of detection and methods of diagnosis.

Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use

The present invention provides binding molecules that include an IgM, IgA, IgG/IgM or IgG/IgA antibody with a modified J-chain that includes a binding moiety that antagonizes a T-cell inhibitory signaling pathway, and their uses.

Binding molecules with modified J-chain

This disclosure provides dimeric, pentameric, and hexameric Tumor Necrosis Factor (TNF) superfamily receptor protein binding molecules and methods of using such binding molecules to direct apoptosis-mediated killing of TNF receptor-expressing cells.

Polynucleotides encoding death domain-containing receptor-5 (DR5) binding molecules

The present invention concerns modified recombinant J-chain polypeptides, binding molecules, such as antibodies comprising the same, and their uses.

Modified J-chain

The present invention concerns binding molecules that comprise an IgM, IgA, IgG/IgM or IgG/IgA antibody with a J-chain modified to include an ADME-modulating moiety, and their uses.

This disclosure provides a multimeric hepatitis B virus (HBV) protein binding molecule, e.g., a dimeric IgA or a pentameric or hexameric IgM binding molecule, comprising at least two bivalent binding units, or variants or fragments thereof, each comprising at least two antibody heavy chain constant regions or fragments thereof, wherein each heavy chain constant region or fragment thereof is associated with an HBV antigen binding domain. The disclosure also provides compositions comprising the multimeric binding molecules, polynucleotides encoding the multimeric binding molecules, and methods to make and use the multimeric binding molecules.

Multi-valent hepatitis B virus antigen binding molecules and uses thereof

The disclosure provides modified human IgM heavy chain constant regions that include one or more amino acid substitutions, e.g., in the C&#x3bc;3 domain, where a modified human IgM antibody comprising the modified IgM constant region and a heavy chain variable region specific for a target antigen exhibits reduced complement-dependent cytotoxicity (CDC) of cells expressing the target antigen relative to a corresponding wild-type human IgM antibody.

Modified human IgM constant regions for modulation of complement-dependent cytolysis effector function

Provided herein are antibodies comprising multiple non-natural amino acid residues at site-specific positions, compositions comprising the antibodies, methods of their production and methods of their use. The antibodies are useful for methods of treatment and prevention, methods of detection and methods of diagnosis.

Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use

Aspects of the invention include isolated anti-PD-L1 antibodies, as well as compositions containing such antibodies, and methods of using the same in the treatment of diseases or conditions that are mediated by PD-L1 signaling.

Anti-PD-L1 antibodies

This disclosure provides an IgM antibody or IgM-like antibody comprising a variant J-chain and/or variant IgM heavy chain constant regions that can confer increased serum half-life upon the antibody.

IgM Fc and J-chain mutations that affect IgM serum half-life

This disclosure provides pentameric and hexameric CD20 binding molecules and methods of using such molecules to direct complement-mediated, T-cell-mediated, or both complement-mediated and T-cell-mediated killing of CD20-expressing cells.

Growing community of inventors

Foster City, CA, United States of America

Ramesh Baliga